Our principal objective is to become a leading company that discovers, develops and commercializes novel, autologous cell therapies and related devices, for the treatment of chronic and acute heart damage. more...
BIOHEART MYOHEART DOSE ESCALATION U.S. CLINICAL STUDY INTERIM RESULTS - Intramyocardial Myoblast Treatment for Ischemic Heart Failure: Results of a Phase I Study. View Article
Ex Vivo Priming of Endothelial Progenitor Cells With SDF-1 Before Transplantation Could Increase Their Proangiogenic Potential. View this Abstract
Download Free Software
To view content of these articles, you may be required to install the following plugins:
Adobe Acrobat Reader
Powerpoint Viewer for Mac
Powerpoint Viewer for Windows
NOTE: Certain sections of this page are currently being updated as they are available. Please check this page in the near future for updates.
Myocell Related Information
Myocell, A Cell-based, Autologous Skeletal Myoblast Therapy for the Treatment of Cardiovascular Diseases.
Husnain Kh Haider, Ye Lei[2], and Muhammad Ashraf[1], [1]University of Cincinnati, Department of Pathology and Laboratory Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0529, USA, Email: haiderkh@ucmail.uc.edu, [2]National University of Singapore, NUMI, Blk MD11, 10 Medical Drive, 117597 Singapore.
Catheter-Based Intramyocardial Injection of Autologous Skeletal Myoblasts (Bioheart's MyoCell™) as a Primary Treatment of Ischemic Hea
rt Failure. Clinical Experience with Six-Month Follow-up.
Pieter C. Smits, M.D. Ph.D., Roberr-Jan M. Van Geuns, M.D., Ph.D., Don Poldermans, M.D., Ph.D., Manolis Bountioukos, M.D., Emile E.M. Onderwater, Chi Hang Lee, M.D., Alex P.W.M. Maat, M.D., Patrick Serruys, M.D., Ph.D. Rotterdam, The Netherlands. Journal of the American College of Cardiology, Vol. 42, No. 12, December 2003.
MYOHEART US Phase I Study - Interim Analysis - January 2007
View powerpoint slideshow
Cellular Therapy For Chronic Myocardial Disease: Nonsurgical Approaches.
Warren Sherman
Myocardial Repair By Percutaneous Cell Transplantation Of Autologous Skeletal Myoblasts As A Stand Alone Procedure In Post Myocardial Infarction Chronic Heart Failure Patients.
Patrick W. Serruys, MD, PhD on behalf of the BIOHEART European 005/006 and 008 study investigators. (3rd Annual Conference on Cell Therapy for Cardiovascular Diseases, New York, January, 2007)
BIOHEART MYOHEART DOSE ESCALATION U.S. CLINICAL STUDY INTERIM RESULTS - Intramyocardial Myoblast Treatment for Ischemic Heart Failure: Results of a Phase I Study.
View Article
Cellular Cardiomyoplasty: Myocardial Regeneration With Satellite Cell Implantation. Chiu RCJ, Zibaitis A and RL Kao, Ann Thorac Surg 1995;60:12-8
View Abstract
Clinical Trials Offer Hope to Patients Willing to Take the Risks.
View Article
Cellular Cardiomyoplasty: Improvement of Left Ventricular Function Correlates with the Release of Cardioactive Cytokines. Henning Ebelt, Mirco Jungblut, Ying Zhang, Thomas Kubin, Sawa Kostin, Antje Technau, Svetlana Oustanina, Sylvia Niebrügge, Jürgen Lehmann, Karl Werdan and Thomas Braun.
Skeletal Myoblast for Cardiac Repair. A presentation from the Third International Conference On Cell Therapy For Cardiovascular Disease held in New York, 16th-19th January 2007.
C2C12 Skeletal Muscle Cells Adopt Cardiac-Like Sodium Current Properties in a Cardiac Cell Environment.
Intra-cardiac transplantation of undifferentiated skeletal muscle cells (myoblasts) has emerged as a promising therapy for myocardial infarct repair and is already undergoing clinical trials.
View Article
Electrophysiological Consequence of Skeletal Myoblast Transplantation in Normal and Infarcted Canine Myocardium. Kristen Fouts, BS, Brian Fernandes, PhD, Niladri Mal, MD, Jinqiu Liu, MD, Kenneth R. Laurita, PhD.
Editorial Commentary on this Article: Infarction size is a far greater contributor to arrhythmia risk than any other factor. Myoblast injections have been shown to reduce scar size by up to 70%. The very slight increase of arrhythmia risk of utilizing myoblasts in healthy tissue is more than totally off set by their ability to reduce scar size, by a long margin. Pluripotent stem cells are slightly less pro-arrhythomogenic when injected in healthy tissue but are far less likely to reduce infarction scar size. The best study with pluripotent stem cells only showed a 30% reduction, mostly due to recovery of hibernating tissue not actual scar tissue reduction. Pluripotent stem cells injected into scar tissue primarily become fibroblasts which does not serve to reduce infarction size. Conclusion: Myoblasts when able to form new contractile muscle in scar tissue and thus reduce MI scar size serve to greatly REDUCE the risk of arrhythmia's. MI size reduction provided by myoblast injections has far greater impact on reducing arrhythmia risk than does slight increased risk caused by injecting myoblasts into healthy tissue. Note - Paper fails to address in short time period myoblasts injected into healthy tissue migrate to scar tissue or disappear from healthy tissue due to venous vacuum loss. |
Repeated Implantation is a More Effective Cell Delivery Method in Skeletal Myoblast Transplantation for Rat Myocardial Infarction. Several clinical trials are underway to determine whether autologous skeletal myoblast transplantation is an effective and safe therapeutic strategy for severe heart failure due to myocardial infarction (MI). It remains unclear whether repeated skeletal myoblast implantation is a feasible and effective cell delivery method for the infarcted myocardium.
Autologous Stem Cells and Transmyocardial Laser Revascularization for Ischemic Heart - Esha Ibrahim, Quan Zhu, D. Glenn Pennington, Charles E. Ganote and Race L. Kao
Intramyocardial Injection Of Skeletal Myoblasts: Long-Term Follow-up with Pressure-Volume Loops. - Steendijk P, Smits PC, Valgimigli M, van der Giessen WJ, Onderwater EE, Serruys PW.
View an Abstract of this Article
From Cardiac Repair To Cardiac Regeneration--Ready To Translate? HC Ott and DA Taylor.
View an Abstract of this Article
Myoblast Transplantation for Heart Repair – A Review of the State of the Field. - Howard J. Leonhardt, Chairman & CEO Bioheart, Inc.
View an Abstract of this Article
Supportive Media: Davos Cell Therapy Meeting Program
Electrophysiological Consequence Of Skeletal Myoblast Transplantation In Normal And Infarcted Canine Myocardium. The purpose of this study is to test a hypothesis that injection of skeletal myoblasts (SkMbs) into viable tissue may alter impulse conduction but that injections into nonviable tissue (scar) will have negligible impact.
Myocell SDF-1
AMD3100 and CD26 Modulate Mobilization, Engraftment, and Survival of Hematopoietic Stem and Progenitor Cells Mediated by the SDF-1/CXCL12-CXCR4 Axis. Hal E Broxmeyer, Giao Hangoc, Scott Cooper, Timothy Campbell, Shigeki Ito, and Charlie Mantel Ann. N.Y. Acad. Sci., March 14, 2007; .
Gene Transfer of Stromal Cell-Derived Factor-1 Enhances Ischemic Vasculogenesis and Angiogenesis via Vascular Endothelial Growth Factor/Endothelial Nitric Oxide Synthase-Related Pathway. Ken-ichi Hiasa, MD; Minako Ishibashi, MD; Kisho Ohtani, MD; Shujiro Inoue, MD; Qingwei Zhao, MD; Shiro Kitamoto, MD; Masataka Sata, MD; Toshihiro Ichiki, MD; Akira Takeshita, MD; Kensuke Egashira, MD.
Expression of Vascular Endothelial Growth Factor, Stromal Cell-Derived Factor-1, and CXCR4 in Human Limb Muscle With Acute and Chronic Ischemia. Vincent van Weel, Leonard Seghers, Margreet R de Vries, Esther J Kuiper, Reinier O Schlingemann, Ingeborg Bajema, Jan H N Lindeman, Pien M Delis-van Diemen, Victor W M van Hinsbergh, J Hajo van Bockel, and Paul H A Quax Arterioscler. Thromb. Vasc. Biol., March 15, 2007;
Cellular, But Not Direct, Adenoviral Delivery of Vascular Endothelial Growth Factor Results in Improved Left Ventricular Function and Neovascularization in Dilated Ischemic Cardiomyopathy.
Myoblast-Mediated Gene Transfer for Therapeutic Angiogenesis and Arteriogenesis
Myoblast Independent and Other Trials
Skeletal Myoblast Transplantation Through A Catheter-Based Coronary Sinus Approach: An Effective Means Of Improving Function Of Infarcted Myocardium.
Endoventricular Transplantation of Allogenic Skeletal Myoblasts in a Porcine Model of Myocardial Infarction. Nabil Dib, MD, MSc; Edward B. Diethrich, MD; Ann Campbell, RN; Noreen Goodwin, RN; Barb Robinson, LVT, LATg; James Gilbert, BA; Dan W. Hobohm, MD; and Doris A. Taylor, PhD.
Adult Stem Cells For Myocardial Repair. Felipe Prósper, Ana Perez, Juana Merino, Gregorio Rábago, Juan Carlos Chachques, Milagros Hernández, Joaquín Barba, Eduardo Alegria, Juan José Gavira, Angel Panizo and Jesús Herreros.
Cell Transplantation Cardiac Special Issue On Cardiac Cell Therapy From Around The World. Special linked table of contents listing Abstracts.
Late-Breaking Clinical Trial News Release 9: Implanting Muscle Cells to Treat Heart Failure Seems Safe, Promising.
MYOBLAST CELL GRAFTING INTO HEART MUSCLE: Cellular Biology and Potential Applications. Annual Review of Physiology, Vol. 61: 219-242 (Volume publication date March 1999) (doi:10.1146/annurev.physiol.61.1.219)
Adipose Derived Cells Research & Related
Proangiogenic Actions Of Adipose Tissue-Derived Mesenchymal Stem Cells In Hindlimb Ischemia Model.
Ex Vivo Priming of Endothelial Progenitor Cells With SDF-1 Before Transplantation Could Increase Their Proangiogenic Potential.
Autologous Transplantation Of Peripheral Blood Endothelial Progenitor Cells (CD34+) For Therapeutic Angiogenesis In Patients With Critical Limb Ischemia
Human Adipose Tissue-Derived Mesenchymal Stem Cells Improve Postnatal Neovascularization In A Mouse Model Of Hindlimb Ischemia
Novel Autologous Cell Therapy In Ischemic Limb Disease Through Growth Factor Secretion By Cultured Adipose Tissue–Derived Stromal Cells
Secretion Of Angiogenic And Antiapoptotic Factors By Human Adipose Stromal Cells
MyoCell III Related
Improved Graft Mesenchymal Stem Cell Survival in Ischemic Heart With a Hypoxia-Regulated Heme Oxygenase-1 Vector.
Cell Transplantation Therapy For End-Stage Heart Failure-Enhanced Efficacy Of Transplantation By Control-Release Of Cell Growth Factor.
Adult Stem Cells for Cardiac Repair: A Choice Between Skeletal Myoblasts and Bone Marrow Stem Cells -- Ye et al. 2.
Combined Autologous Cellular Cardiomyoplasty with Skeletal Myoblasts and Bone Marrow Cells in Canine Hearts for Ischemic Cardiomyopathy. Memon IA, Sawa Y, Miyagawa S, Taketani S, Matsuda H.; Osaka University Graduate School of Medicine, Department of Surgery E1, Division of Cardiovascular Surgery, Osaka, Japan.
Combined Transplantation Of Skeletal Myoblasts And Angiopoietic Progenitor Cells Reduces Infarct Size And Apoptosis And Improves Cardiac Function In Chronic Ischemic Heart Failure. Nikolaos Bonaros, MD, Rauend Rauf, MD, Dominik Wolf, MD, Eva Margreiter, PhD, Alexandar Tzankov, MD, Bernhard Schlechta, MD, Alfred Kocher, MD, Harald Ott, MD, Thomas Schachner, MD, Steffen Hering, PhD, Johannes Bonatti, MD, Guenther Laufer, MD
Combined Transplantation of Skeletal Myoblasts and Bone Marrow Stem Cells for Myocardial Repair in Rats. H.C. Ott, N. Bonaros, R. Marksteiner, D. Wolf, E. Margreiter, T. Schachner, G. Laufer, S. Hering.
Repair of Impaired Myocardium by Means of Implantation of Engineered Autologous Myoblast Sheets. Imran A. Memon, MBBS, PhD, Yoshiki Sawa, MD, PhD, Norihide Fukushima, MD, Goro Matsumiya, MD, Shigeru Miyagawa, MD, PhD , Satoshi Taketani, MD, Satoru K. Sakakida, MD, PhD, Haruhiko Kondoh, MD, PhD, Alexey N. Aleshin, MD, PhD, Tatsuya Shimizu, MD, PhD, Teruo Okano, PhD, Hikaru Matsuda, MD.
Autologous Human Serum for Cell Culture Avoids the Implantation of Cardioverter-defibrillators in Cellular Cardiomyoplasty.
Cell Transplantation After The Coculture of Skeletal Myoblasts and Mesenchymal Stem Cells in the Regeneration of the Myocardium Scar: An Experimental Study in Rats.
Biological Pacemakers
The Biotech Weblog: Engineering Muscle Tissue-Derived Myoblasts Create Electrically-Conducting Tissue For The Heart.
A Biological Pacemaker Created From Patient’s Own Cells
Now, researchers at Children’s Hospital Boston have found out a way to use the patient’s own cells instead of a pacemaker to treat the problems associated with traditional pacemakers. The team, led by Douglas Cowan, PhD, a cell biologist in Children’s Department of Anesthesiology, Perioperative and Pain Medicine, wanted to create some sort of biological substitute for heart block that would, of course, be more natural and more stable. ...
Natural Pacemaker 'Within 10 Years'
The days of the artificial pacemaker may soon be over for millions of people with serious heart problems. Scientists in the United States believe it may one day be possible to use a person's own body tissue to repair damage around the heart. Tests on rats suggest that implanting manipulated tissue back into the body could help people's hearts to beat regularly...
Scientists Develop Technique That May Generate Human Embryonic Stem Cells Without Harming The Embryo.
Advanced Cell Technology, Inc. (ACT) reported that they have developed a technique that may successfully generate human embryonic stem cells using an approach that does not harm embryos.
Researchers Move Biotechnology Closer To Replacing Electronic Pacemakers.
University of California-Davis (UC Davis) researchers have successfully used a custom designed protein and gene delivery system to restore normal heart rhythms in pigs with electronic pacemakers, reducing their dependence on implanted devices. This work suggests that scientists are one step closer to making bioengineering a reality in treating more than 2.2 million Americans affected by irregular heartbeats.
UC Davis Researchers Move Biotechnology Closer to Replacing Electronic Pacemakers.
UC Davis researchers have successfully used a custom designed protein and gene delivery system to restore normal heart rhythms in pigs with electronic pacemakers, reducing their dependence on implanted devices.
Bioartificial Sinus Node Constructed via In Vivo Gene Transfer of an Engineered Pacemaker HCN Channel Reduces the Dependence on Electronic Pacemaker in a Sick-Sinus Syndrome Model.
Tse HF, Xue T, Lau CP, Siu CW, Wang K, Zhang QY, Tomaselli GF, Akar FG, Li RA.
Engineered Cells Could Control Irregular Heartbeat
Natural Tissues Might Replace Implanted Pacemakers In Children, Study Suggests
Editorial: Biological Pacemakers.
"Genetically engineered pacemakers could be a possible alternative to implantable electronic devices for the treatment of bradyarrhythmias." Rajesh G, MBBS, MD, DNB, DM; Johnson Francis, MBBS, MD, DM, FCSI Department of Cardiology, Medical College Hospital, Calicut, Kerala, India.
View PDF Document of this Editorial
Electrical Stimulation
Electrostimulation Induces Cardiomyocyte Predifferentiation Of Fibroblasts.
Electrical Stimulation For Endothelia.
Electrical Stimulation Directly Induces Pre-Angiogenic Responses In Vascular Endothelial Cells By Signaling Through VEGF Receptors.
Acute Electrical Stimulation Increases Extramyocardial Collateral Blood Flow After A Cardiomyoplasty.
Practical Aspects Of Cardiac Tissue Engineering With Electrical Stimulation.
Electrical Stimulation Promotes Angiogenesis in a Rabbit Hind-Limb Ischemia Model.
Heart Failure and EP Studies
Treating Heart Failure: Beyond Standard Therapy
Prevalence and Incidence of Arrhythmias and Sudden Death in Heart Failure
Other Stem Cell Related Studies
Cardiac Stem Cell Therapy Closer To Reality.